Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02559024 · ClinicalTrials.gov registry record · Phase 1
Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer
A Phase 1 study, sponsored by Providence Health & Services.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02559024: Clinical Trial Phase 1 study, sponsored by Providence Health & Services.
NCT02559024 is a Phase 1 study that was terminated before completion, run by Providence Health & Services. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02559024, a Phase 1 study, was terminated before completion, sponsored by Providence Health & Services.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This study will test the ability of an immune modulator, anti-OX40 (MEDI6469) to alter the immune cell environment within colorectal cancer metastases. The drug will be administered to patients before surgical treatment.
Primary Outcome
Patients are seen at least 7 times in clinic and have 3 physical exams and provide interim medical history four times to identify potential side-effects or complications related to the study drug.
Interventions
- DRUG MEDI6469
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2016-03-14 |
| Est. Completion | 2018-10 |
| Phase | Phase 1 |
Why NCT02559024 stopped before completion
NCT02559024 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which MEDI6469 is the first listed.
NCT02559024 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02559024 about?
NCT02559024 is a clinical study titled "Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer". This study will test the ability of an immune modulator, anti-OX40 (MEDI6469) to alter the immune cell environment within colorectal cancer metastases. The drug will be administered to patients before surgical treatment.
What is the current status of trial NCT02559024?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2016-03-14. Estimated completion is 2018-10.
What interventions are being tested in trial NCT02559024?
The interventions under investigation include: MEDI6469 (DRUG).
Who is sponsoring clinical trial NCT02559024?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02559024's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI